Lazard Asset Management
NUVB icon

Lazard Asset Management’s Nuvation Bio NUVB Stock Holding History

Lazard Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673K Buy
+118,474
New +$579K ﹤0.01% 1344

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Lazard Asset Management's NUVB Position: Q2 2026 in Review

Lazard Asset Management opened a new position in Nuvation Bio (NUVB) in Q2 2026: 118,474 shares worth $673K. The stake represents ﹤0.01% of the portfolio and ranks #1344 among its holdings.

244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Lazard Asset Management held 118,474 shares of Nuvation Bio worth $673K as of Q2 2026.
  • Nuvation Bio was a new Lazard Asset Management position in Q2 2026.
  • Nuvation Bio made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1344 holding.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.